-
EP3981403
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3981403
| EP3981403 - COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 25.03.2022 Database last updated on 12.10.2024 | |
| Former | Request for examination was made Status updated on 11.03.2022 | Most recent event Tooltip | 18.08.2024 | New entry: Despatch of communication that application is refused | Applicant(s) | For all designated states Antecip Bioventures II LLC 630 Fifth Avenue, Suite 2000 New York, NY 10111 / US | [2022/15] | Inventor(s) | 01 /
TABUTEAU, Herriot New York, 10111 / US | [2022/15] | Representative(s) | Murgitroyd & Company 165-169 Scotland Street Glasgow G5 8PL / GB | [N/P] |
| Former [2022/15] | Mitchell, Simon James Murgitroyd & Company London Euston House 24 Eversholt Street London NW1 1AD / GB | Application number, filing date | 21191390.0 | 05.11.2014 | [2022/15] | Priority number, date | US201361900354P | 05.11.2013 Original published format: US 201361900354 P | [2022/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3981403 | Date: | 13.04.2022 | Language: | EN | [2022/15] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 11.03.2022 | Classification | IPC: | A61K31/485, A61K31/137, A61P25/00, A61P25/24, A61P25/28, A61K9/20 | [2022/15] | CPC: |
A61K31/137 (EP,IL,KR,MX);
A61K31/485 (EP,IL,KR,MX);
A61K31/138 (IL);
A61K9/0053 (EP,IL);
A61P11/14 (IL);
A61P25/00 (EP,IL);
A61P25/04 (IL);
A61P25/22 (KR);
A61P25/24 (EP,IL);
A61P25/28 (IL);
A61P29/00 (IL);
A61P43/00 (EP,IL);
A61K2300/00 (IL,KR)
(-)
| C-Set: |
A61K31/137, A61K2300/00 (EP);
A61K31/485, A61K2300/00 (EP);
A61K31/485, A61K2300/00, A61K31/137, A61K2300/00 (MX)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/15] | Title | German: | ZUSAMMENSETZUNGEN UND VERFAHREN MIT BUPROPION ODER VERWANDTEN VERBINDUNGEN UND DEXTROMETHORPHAN | [2022/15] | English: | COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN | [2022/15] | French: | COMPOSITIONS ET PROCÉDÉS COMPRENANT DU BUPROPION OU DES COMPOSÉS APPARENTÉS ET DU DEXTROMÉTHORPHANE | [2022/15] | Examination procedure | 13.08.2021 | Examination requested [2022/15] | 11.03.2022 | Date on which the examining division has become responsible | 24.03.2022 | Despatch of a communication from the examining division (Time limit: M04) | 25.07.2022 | Reply to a communication from the examining division | 29.09.2022 | Despatch of a communication from the examining division (Time limit: M04) | 09.02.2023 | Reply to a communication from the examining division | 18.04.2024 | Date of oral proceedings | 13.08.2024 | Minutes of oral proceedings despatched | 19.08.2024 | Despatch of communication that the application is refused, reason: substantive examination {1} | Parent application(s) Tooltip | EP14859589.5 / EP3065742 | Fees paid | Renewal fee | 13.08.2021 | Renewal fee patent year 03 | 13.08.2021 | Renewal fee patent year 04 | 13.08.2021 | Renewal fee patent year 05 | 13.08.2021 | Renewal fee patent year 06 | 13.08.2021 | Renewal fee patent year 07 | 18.11.2021 | Renewal fee patent year 08 | 22.11.2022 | Renewal fee patent year 09 | 22.11.2023 | Renewal fee patent year 10 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]US5350756 (SMITH RICHARD A [US]); | [I]WO2007092329 (AVANIR PHARMACEUTICALS [US], et al); | [I]WO2009006194 (AVANIR PHARMACEUTICALS [US], et al); | [I]WO2012118562 (RHINE PHARMACEUTICALS LLC [US], et al); | [I]WO2013158680 (ANTECIP BIOVENTURES II LLC [US], et al); | by applicant | US19540619003 |